

# Intraoperative Radiation Therapy: A Systematic Review and Meta-Analysis


Rachel B. Fenberg<sup>1,2</sup>, Sarah C. Nyirjesy, MD<sup>1</sup>, Michael M. Li, MD<sup>1</sup>, Mustafa Bulbul, MD<sup>3</sup>, Sidharth Puram, MD, PhD<sup>4</sup>

<sup>1</sup> Department of Otolaryngology – Head and Neck Surgery, The Ohio State University, Columbus, OH

<sup>2</sup> Albert Einstein College of Medicine, Bronx, NY

<sup>3</sup> West Virginia University, Department of Otolaryngology – Head and Neck Surgery

<sup>4</sup> Washington University School of Medicine, Department of Otolaryngology – Head and Neck Surgery



THE OHIO STATE  
UNIVERSITY

WEXNER MEDICAL CENTER

## Background

Intraoperative radiation therapy (IORT) is a treatment modality for head and neck cancer, typically used for local recurrence or gross residual disease. We completed a systematic review and meta-analysis to examine treatment patterns and patient outcomes for IORT administered to treat head and neck cancers.

## Methods

- Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.
- We extracted survival probabilities and percent complications and performed a meta-analysis of proportions.
- Heterogeneity was assessed using I<sup>2</sup>.
- The random effects model was used to pool proportions from included studies.




Figure 1. PRISMA flow diagram showing records searched and included

## Results


### Disease Free Survival and Overall Survival

- Eight studies reported 2-year disease free survival (DFS) and overall survival (OS)
- The pooled 2-year DFS was 48% (95% CI=0.37-0.60)
- The pooled 2-year OS was 45% (95% CI=0.37-0.53)
- There was significant heterogeneity noted, I<sup>2</sup>=81.73% and I<sup>2</sup>=62.43%, respectively.

### Complication Rates

- Twelve studies reported percent complications.
- The pooled proportion of complications for patients undergoing IORT was 23% (95% CI=0.17-0.30).
- There was significant heterogeneity noted as well, I<sup>2</sup>=78.81%.

*The source of heterogeneity could not be further investigated given the paucity of information to perform further analysis.*



Figures 2 and 3. Meta analysis of 2-year DFS and OS

## Conclusions

- The 2-year OS found in our study is less than what is reported in the literature for squamous cell carcinoma, the most common histology in our review and analysis.
- The patient population receiving IORT typically has advanced and invasive disease, making it difficult to conclude what benefit IORT truly had on their outcomes.
- There is no consensus in the literature on the extent of benefits from IORT.
- The significant heterogeneity in our systematic review is evidence that there are conflicting results on the impacts of IORT.
- While there is potential for IORT to create local control and help lead to DFS, further studies are needed to clarify how IORT can be most beneficial for patients.

## References

1. Kyrgias G, Hajjiannou J, Tolia M, Kouloulis V, Lachanas V, Skoulakis C, Skarlatos I, Raptis A, Bizakis I. Intraoperative radiation therapy (IORT) in head and neck cancer: A systematic review. *Medicine (Baltimore)*. 2016 Dec;95(50):e5035. doi: 10.1097/MD.0000000000005035. PMID: 27977569; PMCID: PMC5268015.
2. Chen AM, Garcia J, Bucci MK, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. *Head Neck* 2008;30:2–9.
3. Garrett P, Pugh N, Ross D, Hamaker R, Singer M. Intraoperative radiation therapy for advanced or recurrent head and neck cancer. *Int J Radiat Oncol Biol Phys*. 1987 May;13(5):785-8. doi: 10.1016/0360-3016(87)90300-2. PMID: 3570902.

